Evidence map›Paper›PMID 30013340›Full record

ArticleInternational journal of nanomedicine2018

Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.

Fateme Haghiralsadat, Ghasem Amoabediny, Samira Naderinezhad, Behrouz Zandieh-Doulabi, Tymour Forouzanfar, Marco N Helder

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Review
  9. Targeting the EphA2 pathway: could it be the way for bone sarcomas?Cell communication and signaling : CCS · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Fateme HaghiralsadatDepartment of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
Ghasem AmoabedinyDepartment of Nano Biotechnology, Research Center for New Technologies in Life Science Engineering, amoabedini@ut.ac.ir.
Samira NaderinezhadDepartment of Biotechnology and Pharmaceutical Engineering, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran, amoabedini@ut.ac.ir.
Behrouz Zandieh-DoulabiDepartment of Oral Cell Biology and Functional Anatomy, Academic Center for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam and University of Amsterdam, MOVE Research Institute, Amsterdam, the Netherlands.
Tymour ForouzanfarDepartment of Oral and Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam, amoabedini@ut.ac.ir.
Marco N HelderDepartment of Oral and Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam, amoabedini@ut.ac.ir.
University of Tehran · IRAmsterdam UMC Location Vrije Universiteit Amsterdam · NLAcademic Center for Dentistry Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOsteosarcoma (OS) mostly affects children and young adults, and has only a 20%-30% 5-year survival rate when metastasized. We aimed to create dual-targeted (extracellular against EphA2 and intracellular against JNK-interacting protein 1 [JIP1]), doxorubicin (DOX)-loaded liposomes to treat OS metastatic disease. MATERIALS AND

methodsCationic liposomes contained

resultsCharacteristics assessment showed that 1) size of the bilayered particles was 109 nm; 2) DOX loading efficiency was 87%; 3) siRNA could be successfully loaded at a liposome:siRNA ratio of >24:1; and 4) the zeta potential was 18.47 mV. Tumor-mimicking pH conditions exhibited 80% siRNA and 50.7% DOX sustained release from the particles. Stability studies ensured the protection of siRNA against degradation in serum. OS cell lines showed increased and more pericellular/nuclear localizations when using targeted vesicles. Nontargeted and targeted codelivery caused 70.5% and 78.6% cytotoxicity in OS cells, respectively (free DOX: 50%). Targeted codelivery resulted in 42% reduction in the siRNA target, JIP1 mRNA, and 46% decrease in JIP1 levels.

conclusionOur dual-targeted, DOX-loaded liposomes enhance toxicity toward OS cells and may be effective for the treatment of metastatic OS.

Indexed as

Drug Resistance, MultipleAdaptor Proteins, Signal TransducingApoptosisBone NeoplasmsCationsCell Line, TumorDoxorubicinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansHydrogen-Ion ConcentrationNanoparticlesOsteosarcomaPhosphatidylethanolaminesPolyethylene GlycolsReceptor, EphA2Adaptor Proteins, Signal TransducingCationsDoxorubicinliposomal doxorubicinMAPK8IP1 protein, humanPhosphatidylethanolaminespolyethylene glycol-distearoylphosphatidylethanolaminePolyethylene GlycolsReceptor, EphA2RNA, Small Interferingcationic liposomeextracellular targetingfunctionalizationintracellular targetingMAPK8IP1MAP kinase 8 interacting protein 1

Identifiers

PMID30013340
PMCPMC6039070
OpenAlexW2810236108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.